Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Fasenra for Severe Eosinophilic Asthma

AstraZeneca news release; 2017 Nov 14

The US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for severe eosinophilic asthma. The approval was granted to AstraZeneca (Wilmington, DE).

Indications: Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the add-on maintenance treatment of patients with severe asthma aged ≥12 years, and with an eosinophilic phenotype.

Safety/efficacy: Approval was based on a phase 3 program demonstrating up to a 51% reduction in asthma exacerbations, significant improvement in lung function, and a 75% reduction in daily oral steroid use.

Dosage and administration: Administer by subcutaneous injection. Recommended dose is 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter.

Adverse reactions: Most common adverse reactions (incidence ≥5%) include headache and pharyngitis.


Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma. [news release]. AstraZeneca; Wilmington, DE. November 14, 2017. Accessed November 15, 2017.

This Week's Must Reads

AHA Statement: Accurate Measurement of BP, Hypertension; ePub 2019 Mar 4; Muntner, et al

Coffee Consumption & Plasma Biomarkers, Am J Clin Nutr; ePub 2019 Mar 5; Hang, et al

Is Adding Aspirin to Warfarin Therapy Beneficial? , JAMA Intern Med; ePub 2019 Mar 4; Schaefer, et al

Urinary Oxalate Excretion & Risk of CKD Progression, JAMA Intern Med; ePub 2019 Mar 4; Waikar, et al

Psychosocial Stress & CV Health in Older Women, Circulation; ePub 2019 Feb 28; Burroughs-Peña, et al

Must Reads in FDA Actions

FDA Approves Steglatro for Adults with T2D, Pfizer news release; 2017 Dec 22

FDA Approves Ozempic for Treatment of T2D, Novo Nordisk news release; 2017 Dec 5

FDA Approves Epinephrine Autoinjector for Infants, Kaléo news release; 2017 Nov 20

FDA Approves Fasenra for Severe Eosinophilic Asthma, AstraZeneca news release; 2017 Nov 14

Shingrix Approved for Prevention of Shingles, GSK news release; 2017 Oct 23